Non-Small Cell Lung Carcinoma

Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC

2 weeks ago talkbio0Tagged Accelerated, Approved, Beamion, Boehringer Ingelheim, competition, Confirmatory Trial, Enhertu, erbB-2 Receptor, Frequency of Responses, HER2-mutant, Hernexeos, Identifier, LUNG-1, Mutation, Non-Small Cell Lung Carcinoma, non-squamous NSCLC, Oncomine Dx Target Test, oral targeted therapy, Priority Review, Requirement, TKD, United States Food and Drug Administration, Zongertinib

Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu

ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

3 weeks ago talkbio0Tagged Bio, Combined, Frequency of Responses, IMM2510/AXN-2510, ImmuneOnco, Instill - dosing instruction imperative, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-L1xVEGF, Pharmacotherapy, safety profile

ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

1 month ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

2 months ago talkbio0Tagged ARROS-1 trial, Frequency of Responses, Metastatic malignant neoplasm to brain, Neoplasms, Non-Small Cell Lung Carcinoma, Nuvalent, Protein-tyrosine kinase inhibitor, ROS1-positive Lung Cancer, Submission, United States Food and Drug Administration, zidesamtinib

Nuvalent; ROS1-positive lung cancer; zidesamtinib; FDA submission; ARROS-1 trial; NSCLC; tyrosine kinase inhibitor; objective response rate; brain metastases; oncology

Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss

3 months ago talkbio0Tagged Application procedure, Clinical Trials, Daiichi, Deruxtecan, HER3, Merck, Non-Small Cell Lung Carcinoma, Overall Survival, patritumab, Sankyo, therapeutic autologous dendritic cells, United States Food and Drug Administration, Withdraw (activity)

Merck; Daiichi Sankyo; patritumab deruxtecan; HER3 ADC; FDA application; non-small cell lung cancer; clinical trial; overall survival; application withdrawal

AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer

3 months ago talkbio0Tagged AbbVie, Accelerated, ADC, Approved, Emrelis, Malignant neoplasm of lung, MET protein, human, Non-Small Cell Lung Carcinoma, Protein Overexpression, Solid Neoplasm, Telisotuzumab, therapeutic autologous dendritic cells, United States Food and Drug Administration, vedotin-tllv

AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval

Revolutions KRAS drugs appear competitive in several lung cancer settings

4 months ago talkbio0Tagged Biological Markers, G12C inhibitors, K-ras Oncogene, KRAZATI, Lumakras, Non-Small Cell Lung Carcinoma, Rotation, sotorasib

KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines

AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer

4 months ago talkbio0Tagged AACR25, Boehringer, cellular targeting, durability, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Zongertinib

Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

4 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC

4 months ago talkbio0Tagged Akeso, Combined, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-1/VEGF, Pharmacotherapy, Safety, summit

Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety